海外の治験の状況「1」での検索結果
1993件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Use of biological marker (ABCB1/P-glycoprotein) as factor able to distinguish patients having different risk of recurrence in osteosarcoma
- Non metastatic osteosarcoma of the extremities MedDRA version: 14.0 Level: PT Classification code 10031293 Term: Osteosarcoma localised System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2011-09-02
Authorised
- Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation - Treatment of late hypertension in aortic coarctation
- Aortic coarctation and late hypertension
- Netherlands
- 2006-12-22
Authorised
- A Study to Investigate Dance 501 (Human Insulin Inhalation Solution and Inhaler) in Subjects with Type 1 Diabetes Mellitus (T1DM)
- Type 1 Diabetes Mellitus br>MedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Germany
- 2018-09-25
Authorised
- An extension trial to trial NN1250-3583 comparing safety and efficacy of NN1250 with insulin glargine, both with insulin aspart as meal-time insulin, in type 1 diabetes - BEGIN™: T1
- Type 1 diabetes MedDRA version: 12.1 Level: LLT Classification code 10067584 Term: Type 1 diabetes mellitus
- France, Germany, United Kingdom
- 2010-02-23
Authorised
- study to investigate cetuximab plus irinotecan as rechallenge 3rd-line treatment of kras, nras and braf wild-type irinotecan-pretreated metastatic colorectal cancer patients progressing after an initial response to a 1st-line cetuximab-containing therapy and a standard 2nd-line.
- metastatic colonrectal cancer KRAS, NRAS and BRAF wild type. MedDRA version: 17.0 Level: LLT Classification code 10052362 Term: Metastatic colorectal cancer System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Italy
- 2014-05-16
Authorised
- A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 17.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 16.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- VEGF, VEGFR1 and VEGFR2 expression in serous epithelial ovarian carcinoma, and its association to the efficacy of bevacizumab combined with paclitaxel and carboplatin as first line treatment
- FIGO Stage III-IV serous epithelial ovarian carcinoma
- Finland
- 2005-09-12
Authorised
- A phase I study of azacitidine with Ceplene/interleukin-2 followed by a randomized phase II study of the efficacy and safety of maintenance treatment with azacitidine with or without Ceplene/interleukin-2 in patients with higher risk myelodysplastic syndromes (MDS) who achieved hematological response to azacitidine. - GFM-Aza-ceplene
- Myelodysplastic syndromes MedDRA version: 12.1 Level: LLT Classification code 10028533 Term: Myelodysplastic syndrome
- France
- 2010-07-29
Authorised
- Study of the possibility to increase remnant insulin production in patients with type 1 diabetes using the glucagon-like peptide 1 mimicking drug liraglutide
- Beta-cell function in C-peptide positive type 1 diabetes;Therapeutic area: Diseases [C] - Nutritional and Metabolic Diseases [C18]
- Sweden
- 2015-08-11